Literature DB >> 10850388

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.

I Ieiri1, H Tainaka, T Morita, A Hadama, K Mamiya, M Hayashibara, H Ninomiya, S Ohmori, M Kitada, N Tashiro, S Higuchi, K Otsubo.   

Abstract

This study evaluated the catalytic activity of three variants (Ile, Leu, and Thr) at codon 359 of CYP2C9 enzymes expressed in a yeast cDNA expression system, and then established single-strand conformation polymorphism (PCR-SSCP) analysis for simultaneous detection as a screening method. Diclofenac was used for the in vitro experiment, and its hydroxy metabolite (4'-hydroxydiclofenac) was measured by HPLC. To discuss the in vivo effect of the Thr359 variant on the pharmacokinetics of phenytoin, a case report is presented. The efficiency of the SSCP method was evaluated by analyzing DNA samples from a homozygote for Ile359 and a heterozygote for Leu359 or Thr359. To evaluate the interaction between the P450 level and reductase activity, two batches of the Thr359 variant with a different P450:reductase activity ratio (1:4.0 and 1:1.4) were used. The in vitro study revealed that recombinant Ile359, Leu359, and Thr359 (2 batches) possessed a mean Km of 2.0, 16.5 and (3.8 and 2.9) micromol and Vmax of 12.4, 17.9 and (4.4 and 5.1) nmol/min/nmol P450, respectively. Although the magnitude of the change in catalytic efficiency for the Thr359 variant was close to that of the Leu359 variant, the effect of the two variants on diclofenac 4'-hydroxylation appears to be different because Leu359 variant was associated with a high Km, and Thr359 with a low Vmax. No significant differences in the kinetic data were observed between the two Thr359 enzymes, suggesting that low reductase activity in the Thr359 enzyme was not a major determinant in the present in vitro experiment. Estimated pharmacokinetic parameters of phenytoin obtained by the Bayesian method in an epileptic patient who was a heterozygote carrier for Thr359 variant were: Km = 6.45 microg/mL, Vmax = 5.77 mg/kg/d, and Vmax/Km = 0.89 L/kg/day. The Vmax/Km value in this patient was similar to the population mean value (0.90 L/kg/day) in Japanese heterozygotes for the Leu359 variant. Results for PCR-SSCP were in complete agreement with those obtained using established methods. Thus, the PCR-SSCP approach is useful for identifying these three variants of the CYP2C9 gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10850388     DOI: 10.1097/00007691-200006000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  15 in total

Review 1.  Pharmacogenetics of asthma.

Authors:  A Fenech; Ian P Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

2.  No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3.

Authors:  Tadaaki Hanatani; Tsuyoshi Fukuda; Sachi Onishi; Yoshihiko Funae; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

3.  The rules of variation: amino acid exchange according to the rotating circular genetic code.

Authors:  Fernando Castro-Chavez
Journal:  J Theor Biol       Date:  2010-04-03       Impact factor: 2.691

Review 4.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 5.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors:  Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-12-12       Impact factor: 4.200

Review 7.  Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.

Authors:  Larisa H Cavallari; Jaekyu Shin; Minoli A Perera
Journal:  Pharmacotherapy       Date:  2011-12       Impact factor: 4.705

8.  Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.

Authors:  Julia Kirchheiner; Ingolf Meineke; Göran Müller; Steffen Bauer; Wolfgang Rohde; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Authors:  Julie A Johnson; Larisa H Cavallari
Journal:  Pharmacol Rev       Date:  2013-05-17       Impact factor: 25.468

Review 10.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.